NASDAQ · Medical Devices · USD
SI-BONE, Inc. (SIBN) Stock Analysis
SI-BONE, Inc. (SIBN) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SIBN Key Statistics
As of Oct 21, 2026Trading
- Open
- $20.39
- Previous Close
- $20.54
- Day's Range
- 20.28–21.22
- 52-Week Range
- 11.48–21.89
- Volume
- 812.75K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.66
Valuation
- Market Cap
- $933.12M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 4.37
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.34
Financials (FY)
- Revenue (FY)
- $200.93M+20.19%
- Net Income (FY)
- −$18.90M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −6.85%
- Shares Outstanding
- 44.82M
- 1-Year Return
- +34.15%
Dividend and dates
- Earnings Date
- November 2, 2026
- Avg Volume
- 557.35K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, SIBN closed at $20.82, +34.15% over 1 year.
SI-BONE, Inc. (SIBN) has a market capitalization of $933.12M.
In fiscal 2025, SIBN reported revenue of $200.93M.
SIBN Stock Return by Calendar Year
SI-BONE, Inc. (SIBN) return since Oct 2018: what $10,000 became
- 1 year
- $10,000 $13,415
- +34.15%
- 5 years
- $10,000 $9,370
- −6.30%
- Since Oct 2018
- $10,000 $10,379
- +3.79%
If you had invested $10,000 in SI-BONE, Inc. (SIBN) at the close on October 17, 2018, the earliest close on record here, it would have been worth $10,379 at the close on October 21, 2026: +3.79% in total, +0.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +5.58% |
| 2025 | +40.66% |
| 2024 | −33.21% |
| 2023 | +54.34% |
| 2022 | −38.77% |
| 2021 | −25.72% |
| 2020 | +39.07% |
| 2019 | +2.92% |
| 2018 (partial year) | +4.14% |
As of October 21, 2026.
SIBN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $200.93M | −$18.90M | −9.4% |
| 2024 | $167.18M | −$30.91M | −18.5% |
| 2023 | $138.89M | −$43.34M | −31.2% |
| 2022 | $106.41M | −$61.26M | −57.6% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $200.93M | $159.88M | −$22.33M | −$18.90M | −9.4% |
| 2024 | $167.18M | $132.12M | −$35.25M | −$30.91M | −18.5% |
| 2023 | $138.89M | $109.42M | −$46.93M | −$43.34M | −31.2% |
| 2022 | $106.41M | $90.70M | −$59.61M | −$61.26M | −57.6% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
SIBN Valuation vs Medical Devices Median
Median of 145 stocks| Metric | SIBN | Medical Devices median | vs median |
|---|---|---|---|
| P/S ratio | 4.37 | 2.53 | 73% above |
| Profit margin | −6.85% | −14.78% | 7.9 pts above |
Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
YahooTruist Securities Maintains Buy on SI-BONE, Raises Price Target to $25
BenzingaSI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
YahooSI-BONE Receives FDA Clearance For Its iFuse Granite Onyx System
BenzingaSI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlphaSI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
Yahoo
All 14 articles ↓Show fewer ↑
UBS Maintains Buy on SI-BONE, Raises Price Target to $25
BenzingaTruist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
BenzingaTD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
BenzingaSI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
SeekingAlphaSI-BONE (NASDAQ:SIBN) Beats EPS and Raises Guidance, But Shares Slip
ChartMillSI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est
BenzingaSI-BONE Q2 EPS $(0.09) Beats $(0.15) Estimate, Sales $56.010M Beat $55.335M Estimate
BenzingaUBS Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $24
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Devices Stocks
Abbott Laboratories
$173.92B
MDTMedtronic plc.
$119.00B
SYKStryker Corporation
$114.15B
BSXBoston Scientific Corporation
$64.33B
EWEdwards Lifesciences Corporation
$50.95B
GEHCGE HealthCare Technologies Inc.
$31.17B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B











